# PSMA immunohistochemistry as a diagnostic biomarker of hepatocellular carcinoma

**Authors:** Killian Véron, Etienne Becht, Astrid Laurent-Bellue, Rémy Nicolle, Miguel Albuquerque, Samira Laouirem, Hélène Cazier, Clément Bailly, Mohamed Bouattour, Mickaël Lesurtel, Catherine Guettier, Rachida Lebtahi, Valérie Vilgrain, Valérie Paradis, Jérôme Cros, Aurélie Beaufrère

PMC · DOI: 10.1016/j.jhepr.2025.101542 · JHEP Reports · 2025-07-31

## TL;DR

PSMA is a promising new marker for diagnosing liver cancer, outperforming existing tests and improving accuracy when combined with other markers.

## Contribution

PSMA is shown to be a superior diagnostic biomarker for hepatocellular carcinoma compared to the standard marker panel.

## Key findings

- PSMA has 95% sensitivity and 77% specificity for diagnosing HCC.
- Adding PSMA to existing markers increases diagnostic accuracy to 86%.
- PSMA expression correlates with histoprognostic factors in HCC.

## Abstract

A combination of three immunohistological markers (Glypican 3, heat shock protein 70 [HSP70], and glutamine synthetase [GS]) is routinely used to differentiate hepatocellular carcinoma (HCC), but this panel’s sensitivity is suboptimal. Our aim was to assess the diagnostic value of prostate-specific membrane antigen (PSMA) expression for diagnosing HCC in a series of hepatocellular nodules and compare its performance with that of routinely used markers.

We included 320 hepatocellular nodules from 188 patients in a test cohort and 87 hepatocellular nodules from 48 patients in an external validation cohort distributed as follows: regenerative nodules (RN, n = 39+22), low-grade dysplastic nodules (LGDN, n = 38+16), high-grade dysplastic nodules (HGDN, n = 30+8), early HCC (≤2-cm nodules) (n = 107+24), HCC (n = 106+17), and corresponding non-tumour livers (NTL, n = 152+37). PSMA, HSP70, Glypican 3, and GS expression was assessed by immunohistochemistry on tissue microarrays. For each marker or combination of markers, sensitivity, specificity, and accuracy were calculated.

In the test cohort, PSMA was expressed in 83% of HCC (n = 88/106), 77% of early HCC (n = 82/107), 27% of HGDN (n = 8/30), 21% of LGDN (n = 8/38), 18% of RN (n = 7/39), and 3% of NTL (n = 5/152). In the validation cohort, the sensitivity and specificity of PSMA for HCC diagnosis were 0.95 and 0.77, respectively, and its accuracy was 0.83. The sensitivity and the specificity of the Glypican 3–HSP70–GS (≥2 positive markers) combination for HCC diagnosis were 0.41 and 0.99, respectively, and its accuracy was 0.80. Adding PSMA to this combination increased the sensitivity and accuracy to 0.85 and 0.86, respectively.

PSMA alone has shown good performance in diagnosing HCC, outperforming the combination of the three routinely used markers. When sufficient material is available, adding Glypican 3, HSP70, and GS to PSMA could be recommended.

Differentiating hepatocellular nodules, particularly high-grade dysplastic nodules and hepatocellular carcinoma (HCC), based on histologic criteria remains challenging. In this study, we assess the diagnostic value of a new immunohistochemical marker, prostate-specific membrane antigen (PSMA), for diagnosing HCC in two independent series of hepatocellular nodules and compare its performance with that of routinely used markers (Glypican 3, heat shock protein 70 [HSP70], and glutamine synthetase [GS]). PSMA alone has demonstrated good performance in diagnosing HCC, superior to the combination of the three routinely used markers, and could be useful in practice for differentiating difficult-to-classify hepatocellular nodules. When the material is sparse, using PSMA alone could be recommended, whereas when sufficient material is available, adding PSMA to Glypican 3, HSP70, and GS may be advised, as this combination has shown the best performance for HCC diagnosis.

Image 1

•PSMA demonstrates good diagnostic performance for HCC (sensitivity of 0.95 and specificity of 0.77).•PSMA demonstrates superior diagnostic performance for HCC compared with routinely used markers.•Adding PSMA to routine markers enhances sensitivity and accuracy.•PSMA expression correlates with histoprognostic factors in HCC.

PSMA demonstrates good diagnostic performance for HCC (sensitivity of 0.95 and specificity of 0.77).

PSMA demonstrates superior diagnostic performance for HCC compared with routinely used markers.

Adding PSMA to routine markers enhances sensitivity and accuracy.

PSMA expression correlates with histoprognostic factors in HCC.

## Linked entities

- **Proteins:** FOLH1 (folate hydrolase 1), GPC3 (glypican 3), HSPA1A (heat shock protein family A (Hsp70) member 1A), APC (APC regulator of Wnt signaling pathway)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, GLUL (glutamate-ammonia ligase) [NCBI Gene 2752] {aka DEE116, GLNS, GS, PIG43, PIG59}, FOLH1 (folate hydrolase 1) [NCBI Gene 2346] {aka FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM}
- **Diseases:** NTL (MESH:D008113), dysplastic (MESH:D004416), HCC (MESH:D006528), HGDN (MESH:D008228), tumour (MESH:D009369), RN (MESH:D016606)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12529368/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12529368/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12529368/full.md

---
Source: https://tomesphere.com/paper/PMC12529368